RICH Stock Overview
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Laboratorios Richmond S.A.C.I.F. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AR$849.50 |
52 Week High | AR$1,235.00 |
52 Week Low | AR$380.50 |
Beta | 0.36 |
1 Month Change | -2.91% |
3 Month Change | 21.53% |
1 Year Change | 109.75% |
3 Year Change | 416.41% |
5 Year Change | 2,078.21% |
Change since IPO | 2,195.95% |
Recent News & Updates
Recent updates
Shareholder Returns
RICH | AR Pharmaceuticals | AR Market | |
---|---|---|---|
7D | -0.9% | -2.5% | 2.2% |
1Y | 109.8% | -10.3% | 373.9% |
Return vs Industry: RICH exceeded the AR Pharmaceuticals industry which returned -12.2% over the past year.
Return vs Market: RICH underperformed the AR Market which returned 386.9% over the past year.
Price Volatility
RICH volatility | |
---|---|
RICH Average Weekly Movement | 10.7% |
Pharmaceuticals Industry Average Movement | 5.8% |
Market Average Movement | 10.0% |
10% most volatile stocks in AR Market | 15.5% |
10% least volatile stocks in AR Market | 7.6% |
Stable Share Price: RICH's share price has been volatile over the past 3 months.
Volatility Over Time: RICH's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1935 | 620 | Juan Manuel Artola | https://www.richmondlab.com |
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple sclerosis. The company sells its products in Latin America, Africa, Asia, and the Middle East.
Laboratorios Richmond S.A.C.I.F. Fundamentals Summary
RICH fundamental statistics | |
---|---|
Market cap | AR$68.60b |
Earnings (TTM) | -AR$4.79b |
Revenue (TTM) | AR$8.46b |
8.1x
P/S Ratio-14.3x
P/E RatioIs RICH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RICH income statement (TTM) | |
---|---|
Revenue | AR$8.46b |
Cost of Revenue | AR$3.31b |
Gross Profit | AR$5.15b |
Other Expenses | AR$9.93b |
Earnings | -AR$4.79b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -59.26 |
Gross Margin | 60.84% |
Net Profit Margin | -56.56% |
Debt/Equity Ratio | 239.5% |
How did RICH perform over the long term?
See historical performance and comparison